CN110506044A - 一种brd4抑制剂及其制备和应用 - Google Patents
一种brd4抑制剂及其制备和应用 Download PDFInfo
- Publication number
- CN110506044A CN110506044A CN201880024931.1A CN201880024931A CN110506044A CN 110506044 A CN110506044 A CN 110506044A CN 201880024931 A CN201880024931 A CN 201880024931A CN 110506044 A CN110506044 A CN 110506044A
- Authority
- CN
- China
- Prior art keywords
- substituted
- unsubstituted
- group
- compound
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及一类BRD4蛋白的小分子抑制剂，具体涉及一类具有三氮唑并氮杂结构的小分子化合物、其制备方法、药物组合物和在制备BRD4小分子抑制剂，或预防和/或治疗与BRD4相关的疾病，尤其是癌症，的药物中的用途。
Description
PCT国内申请，说明书已公开。
Claims (12)
- PCT国内申请，权利要求书已公开。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710240864.4A CN108727380A (zh) | 2017-04-13 | 2017-04-13 | 一种brd4抑制剂及其制备和应用 |
| CN2017102408644 | 2017-04-13 | ||
| PCT/CN2018/083098 WO2018188660A1 (zh) | 2017-04-13 | 2018-04-13 | 一种brd4抑制剂及其制备和应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110506044A true CN110506044A (zh) | 2019-11-26 |
| CN110506044B CN110506044B (zh) | 2022-07-05 |
Family
ID=63792269
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710240864.4A Pending CN108727380A (zh) | 2017-04-13 | 2017-04-13 | 一种brd4抑制剂及其制备和应用 |
| CN201880024931.1A Active CN110506044B (zh) | 2017-04-13 | 2018-04-13 | 一种brd4抑制剂及其制备和应用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710240864.4A Pending CN108727380A (zh) | 2017-04-13 | 2017-04-13 | 一种brd4抑制剂及其制备和应用 |
Country Status (2)
| Country | Link |
|---|---|
| CN (2) | CN108727380A (zh) |
| WO (1) | WO2018188660A1 (zh) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111518045A (zh) * | 2019-02-02 | 2020-08-11 | 博诺康源(北京)药业科技有限公司 | 一种具有苯并七元环结构的化合物、其制备方法及用途 |
| CN115043770B (zh) * | 2022-07-21 | 2023-09-08 | 南京大学 | 一种吲哚/氮杂吲哚类化合物的光诱导合成方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011054844A1 (en) * | 2009-11-05 | 2011-05-12 | Glaxosmithkline Llc | Condensed azepine derivatives as bromodomain inhibitors |
| CN102781943A (zh) * | 2009-11-05 | 2012-11-14 | 葛兰素史密丝克莱恩有限责任公司 | 苯并二氮杂*溴结构域抑制剂 |
| CN104781259A (zh) * | 2012-09-28 | 2015-07-15 | 拜耳制药股份公司 | 抑制bet蛋白的5-芳基三唑并氮杂* |
-
2017
- 2017-04-13 CN CN201710240864.4A patent/CN108727380A/zh active Pending
-
2018
- 2018-04-13 WO PCT/CN2018/083098 patent/WO2018188660A1/zh active Application Filing
- 2018-04-13 CN CN201880024931.1A patent/CN110506044B/zh active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011054844A1 (en) * | 2009-11-05 | 2011-05-12 | Glaxosmithkline Llc | Condensed azepine derivatives as bromodomain inhibitors |
| CN102781943A (zh) * | 2009-11-05 | 2012-11-14 | 葛兰素史密丝克莱恩有限责任公司 | 苯并二氮杂*溴结构域抑制剂 |
| CN104781259A (zh) * | 2012-09-28 | 2015-07-15 | 拜耳制药股份公司 | 抑制bet蛋白的5-芳基三唑并氮杂* |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108727380A (zh) | 2018-11-02 |
| WO2018188660A1 (zh) | 2018-10-18 |
| CN110506044B (zh) | 2022-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI736566B (zh) | Ｔｌｒ７/８拮抗劑及其用途 | |
| CN109803962B (zh) | 囊性纤维化跨膜传导调控蛋白的调节剂、以及药物组合物 | |
| CN108347943B (zh) | 乙肝核心蛋白调节剂 | |
| TWI825398B (zh) | Glp-1 受體促效劑、包含該促效劑之醫藥組成物及其製備方法 | |
| CN104379574B (zh) | 用于抑制abl1、abl2和bcr‑abl1的活性的苯甲酰胺衍生物 | |
| EP3057422B1 (en) | Quinolinyl modulators of ror(gamma)t | |
| TW201920094A (zh) | 雜環化合物及其用途 | |
| CN115803030A (zh) | 用于kras靶向降解的化合物和方法 | |
| EP3510025B1 (en) | Heteroaryl inhibitors of pad4 | |
| CN113164761A (zh) | α-1抗胰蛋白酶的调节剂 | |
| CN113286794A (zh) | Kras突变蛋白抑制剂 | |
| TW201443023A (zh) | 作爲ｒｏｃｋ抑制劑之酞□酮及異喹啉酮 | |
| WO2001023383A1 (fr) | Composes de quinuclidine et medicaments contenant ces composes comme principe actif | |
| TW201609725A (zh) | 作為抗癌劑之新穎三環化合物 | |
| CN106459009A (zh) | 丙肝病毒抑制剂及其制药用途 | |
| CN103619817A (zh) | 新颖的二环含氮杂芳基tgr5受体调节剂 | |
| CN113302183A (zh) | 环脲 | |
| JP2017527569A (ja) | オレキシン−１受容体の阻害剤としての治療用化合物 | |
| TWI773718B (zh) | 聚-adp核糖聚合酶（parp）抑制劑 | |
| WO2023059581A1 (en) | Heterobifunctional compounds and their use in treating disease | |
| CN101668747A (zh) | 四氢异喹啉-1-酮衍生物或其盐 | |
| CN115413279A (zh) | P2x3调节剂 | |
| EP3239142A1 (en) | Condensed heterocyclic compound | |
| CN110506044B (zh) | 一种brd4抑制剂及其制备和应用 | |
| CN111801100A (zh) | 用于治疗和预防肝癌的7-取代的磺亚氨酰基嘌呤酮化合物和衍生物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |